Phase III Data In Suspected NASH Boost Madrigal’s Profile, But Bigger Data To Come

Resmetirom, Madrigal’s THRβ agonist, demonstrates safety and tolerability, and succeeds on secondary efficacy endpoints in a study serving as a precursor to the firm’s pivotal Phase III trial.